In a report released today, Chris Shibutani from Cowen & Co. maintained a Buy rating on Seres Therapeutics (MCRB). The company’s shares opened today at $6.42.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 4.7% and a 47.6% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Five Prime Therapeutics, Nektar Therapeutics, and United Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Seres Therapeutics with a $15.50 average price target, which is a 141.4% upside from current levels. In a report issued on February 22, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $16 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.02 and a one-year low of $4.42. Currently, Seres Therapeutics has an average volume of 111.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seres Therapeutics, Inc. is a microbiome therapeutics platform company, which engages in the development of biological drugs. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
